Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade

Documenti analoghi

• Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade
  di: Hata N, et al.
  Pubblicazione: (2016-11-01)
• Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
  di: Cairncross, J. Gregory, et al.
  Pubblicazione: (2014)
• Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status
  di: Hata, Nobuhiro, et al.
  Pubblicazione: (2017)
• AT-56 TREATMENT OF LARGE LOW-GRADE OLIGODENDROGLIAL TUMORS WITH UPFRONT PROCARBAZINE, LOMUSTINE, AND VINCRISTINE CHEMOTHERAPY WITH LONG FOLLOW-UP: A RETROSPECTIVE COHORT STUDY WITH GROWTH KINETICS
  di: Taal, Walter, et al.
  Pubblicazione: (2014)
• Procarbazine, CCNU, and Vincristine Chemotherapy in Gliomatosis Cerebri
  di: Lee, Hyun Gon, et al.
  Pubblicazione: (2014)